Hugo Castro-Malaspina, Richard E. Harris, James Gajewski, Norma Ramsay, Robert Collins, Bernie Dharan, Roberta King, and H.

Size: px
Start display at page:

Download "Hugo Castro-Malaspina, Richard E. Harris, James Gajewski, Norma Ramsay, Robert Collins, Bernie Dharan, Roberta King, and H."

Transcription

1 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program Hugo Castro-Malaspina, Richard E. Harris, James Gajewski, Norma Ramsay, Robert Collins, Bernie Dharan, Roberta King, and H. Joachim Deeg Between April 1988 and July 1998, 510 patients with myelodysplastic syndromes (MDS) underwent unrelated donor bone marrow transplantation (BMT) facilitated by the National Marrow Donor Program. Median age was 38 years (range, <1-62 years). Several conditioning regimens and graft-versus-host disease (GVHD) prophylaxis methods were used, and T-cell depletion was used in 121 patients. Donors were serologically matched for HLA-A, -B, and -DRB1 antigens for 74% of patients. Of 437 patients evaluable for engraftment, 24 (5% cumulative incidence, with 95% confidence interval [CI] of 3%- 7%) failed to engraft, and an additional 33 (8% cumulative incidence; 95% CI, 6%- 10%) had late graft failure. Grades II to IV GVHD developed in 47% of patients (95% Introduction CI, 43%-49%), and limited and extensive chronic GVHD developed at 2 years in 27% (95% CI, 24%-30%). The incidence of relapse at 2 years was 14% (95% CI, 11%-17%). Greater relapse was independently associated with advanced MDS subtype and no acute GVHD. The estimated probability of disease-free survival (DFS) at 2 years was 29% (95% CI, 25%- 33%). Improved DFS was independently associated with less advanced MDS subtype, higher cell dose, recipient cytomegalovirus (CMV) seronegativity, shorter interval from diagnosis to transplantation, and transplantation in recent years. Common causes of death were treatmentrelated complications accounting for 82% of fatalities. The 2-year cumulative incidence of treatment-related mortality (TRM) was 54% (95% CI, 53%-61%). Sixty-nine percent of TRM occurred within the first 100 days, and 93% occurred within the first year of transplantation. Higher TRM was independently associated with older recipient and donor age, HLA mismatch, and recipient CMV seropositivity. This study demonstrates that unrelated donor BMT cures a significant proportion of patients with MDS. TRM is the major problem limiting the success of unrelated donor BMT in MDS. The observations made in this study should facilitate the design of prospective trials aimed at improving the results of unrelated donor stem cell transplantation for MDS. (Blood. 2002;99: ) 2002 by The American Society of Hematology Allogeneic hematopoietic stem cell transplantation is the only curative therapy available for patients with myelodysplastic syndrome (MDS). Single-center experience 1-7 and registry data 8,9 have clearly shown that bone marrow transplantation (BMT) from HLA-matched siblings can cure 40% to 50% of patients with MDS. The main obstacles limiting the success of BMT in these patients have been disease relapse and treatment-related mortality (TRM). 1-9 Outcomes after related donor stem cell transplantation have been extensively studied. Disease-free survival is strongly correlated with patient age, MDS subtype, prognostic score, and chromosomal abnormalities. 1,2,5,6,8,9 Relapse is associated with MDS subtype, prognostic score, chromosomal abnormalities, and disease duration. 1-9 TRM is strongly correlated with disease duration, patient age, and HLA matching. 1-9 Unfortunately, approximately only one third of patients with MDS eligible for allogeneic BMT have a suitable HLA-matched related donor. Therefore, unrelated donor stem cell transplantation has the potential for use in large numbers of patients with MDS. Only a few studies, generally including small numbers of patients receiving transplants from unrelated donors, have been published The impact of patient, disease, transplant, and donor characteristics on outcome after unrelated donor BMT for MDS is not well known. We report here the posttransplantation outcomes of the first 510 unrelated donor BMTs performed as therapy for MDS using marrow from volunteer donors recruited through the National Marrow Donor Program (NMDP). Patients and methods Patients The study population consisted of 510 patients with MDS who received marrow transplants at 87 NMDP-approved transplantation centers (76 in the United States and 11 in Canada, Europe, and Israel) between April 1988 and July During this time, an additional 24 patients underwent unrelated donor transplantation but were not included in this study because they had undergone prior stem cell transplantation (20 autologous, 4 From the National Marrow Donor Program, Minneapolis, MN; Memorial Sloan- Kettering Cancer Center, New York, NY; Children s Hospital Medical Center, Cincinnati, OH; MD Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis; Baylor-Sammons Cancer Center and University of Texas Southwestern Medical Center, Dallas; and Fred Hutchinson Cancer Center, Seattle, WA. Submitted January 26, 2001; accepted October 31, Supported by the MDS Foundation (H.C.-M.), National Institutes of Health grant HL (H.J.D.), the National Marrow Donor Program, the Health Resources and Services Administration (grant ), and the Office of Naval Research (N ) to the National Marrow Donor Program. Reprints: Hugo Castro-Malaspina, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; castro-h@mskcc.org. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked advertisement in accordance with 18 U.S.C. section by The American Society of Hematology BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER

2 1944 CASTRO-MALASPINA et al BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 allogeneic). In 4 of the 510 patients, information on relapse status was unavailable. The diagnosis of MDS and MDS subtypes was established by the centers according to the well-established criteria of the French-American- British classification system. 18 Diagnoses were confirmed or adjusted, if indicated, by the NMDP data center based on reported hematologic features. Patients with hypocellular MDS and less than 5% marrow blasts and MDS patients with neutropenia, thrombocytopenia, or both but without anemia were classified as having refractory anemia (RA; this term was used as an equivalent of refractory cytopenia). Patients with MDS with myelofibrosis, patients whose blood and marrow pictures could not fit the French-American-British criteria (unclassifiable MDS), and patients in whom the MDS subtype at diagnosis was not known were also included in this study. Children with juvenile myelomonocytic leukemia and adults with the myeloproliferative form of chronic myelomonocytic leukemia (CMML) 19 were excluded. One hundred forty-seven patients with MDS whose disease had evolved to acute leukemia before transplantation were included. Forty-seven of these 147 patients underwent chemotherapy and achieved remission before starting conditioning. Transformation to acute leukemia was defined by blood or marrow blast count greater than 30%. 20 The distribution of MDS subtypes at the time of diagnosis and before transplantation is summarized in Table 1. For analyses of transplantation outcomes, patients with refractory anemia with ringed sideroblasts (RARS), CMML (myelodysplastic form), MDS with myelofibrosis, and unknown or unclassifiable MDS were grouped together because of small numbers. Seventy-four patients with advanced MDS (5% or more blasts) or in blastic transformation who achieved hematologic remission (marrow blast count less than 5% and normal peripheral counts) or a second RA phase (marrow blast count less than 5% and persistently subnormal blood counts after chemotherapy) were also analyzed together because they had similar outcomes. Fifty-eight patients with advanced MDS or in blastic transformation whose disease did not change or changed to a different subtype without achieving hematologic remission after chemotherapy were analyzed in their original group. For example, a patient in blastic phase with more than 30% blasts who had a marrow blast count between 5% and 30% after chemotherapy was included for analysis in the acute myelocytic leukemia (AML) group. Classification of patients according to their risk category using a recently published International Prognostic Scoring System 21 was not possible because most data collection occurred before publication of the scoring system. All patients or their guardians signed informed consent for transplantation and for submission of data to the NMDP. Informed consent was approved by the local transplant center Institutional Review Board or its equivalent. Pretransplantation and transplantation characteristics of all patients are summarized in Table 2. The most common preparative regimen was fractionated or single-dose total body irradiation (TBI) plus cyclophosphamide (CY), alone or in combination with other chemotherapeutic agents in 335 (66%) patients, or chemotherapy alone, usually busulfan (BU) plus CY alone or in combination with other chemotherapeutic agents in 128 (25%) patients. Graft-versus-host disease (GVHD) prophylaxis included a variety of in vivo pharmacologic and ex vivo T-cell depletion methods. One hundred twenty-one patients received T-cell depleted marrow grafts, and Table 1. MDS subtypes at diagnosis and before transplantation MDS subtype At diagnosis Before transplantation RA RARS 11 9 RAEB RAEB-t CMML (nonproliferative form) Myelofibrotic MDS 12 8 Unclassifiable or unknown MDS subtype 12 2 Acute myelocytic leukemia In complete remission or in second RA phase 0 74 RARS indicates refractory anemia with ringed sideroblasts. Table 2. Patient and donor characteristics Characteristics 389 patients received T-cell replete marrow grafts. Most recipients of T-cell depleted marrow grafts also underwent posttransplantation in vivo GVHD prophylaxis. The most common pharmacologic in vivo GVHD prophylaxis was a cyclosporine-based regimen, which was used in 326 (64%) patients. Donor recipient HLA matching No. patients Total patients in study 510 Median recipient age, y (range) 38 ( 1-62) Recipient age distribution, y 20 or younger or older 74 Sex, donor:recipient M:F 112 M:M 190 F:M 101 F:F 107 Median time from diagnosis to transplantation, mo (range) 9 ( 1-246) Etiology Idiopathic 398 Postradiation, chemotherapy, or both 70 Postaplastic anemia 26 Post-MPD (polycythemia vera, essential thrombocythemia) 3 Other disease 4 Unknown 9 Cytogenetics Normal 126 Abnormal 238 Failure/unknown 146 Recipient CMV serology Positive 272 Negative 234 Unknown 4 HLA-A, -B, -DRB1 matching HLA-A, -B, -DR identical 376 Allele potential identical 24 Mismatch 110 Preparative regimen TBI/CY other 317 BU/CY other 128 TBI/BU/CY 18 Other 47 GVHD prophylaxis T-cell depletion 121 CSA other 326 Other 63 Median cell dose (range) Non T-cell depletion ( 10 8 nucleated cells/kg) 2.9 ( ) T-cell depletion ( 10 8 nucleated cells/kg) 0.8 ( ) Donor Median age, y (range) 37 (19-59) No. males 302 CMV seropositivity 186 The technology of HLA typing has significantly evolved in the 10-year study period. Donor and recipient HLA typing was performed by the standard serologic microcytotoxicity method (100% of HLA-A and -B and 10% of HLA-DR) and low- to high-resolution DNA-based methods, primarily sequence-specific oligonucleotide probe typing (90% of HLA- DR). Unrelated donor selection was based on matching at the level of resolution available at the time of transplantation. To accommodate the

3 BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 UNRELATED DONOR TRANSPLANTATION FOR MDS 1945 resultant variability in HLA typing data, HLA match between recipient and donor was defined as one of these categories: (1) known match donor and recipient typing were at the same level of resolution and matched perfectly (eg, DRB vs DRB1*0101); (2) potential match donor and recipient typing were reported at different levels of resolution (eg, DRB1*03 vs DRB1*0301) so that at the lowest level of resolution (DRB1*03), the pair was defined as a potential match, but it could not be determined whether a match existed at the higher level of resolution (DRB1*0301); (3) known mismatch donor and recipient typing, regardless of level of resolution reported, could not possibly match (eg, DRB1*0101 vs DR4). Among the 510 patients, 376 (74%) received marrow from a donor who was a known match at HLA-A, -B, and -DR, 110 (22%) received marrow from a donor who was a known mismatch at HLA-A, -B, and -DR, and 24 (5%) received marrow with a potential match at HLA-A, -B, and -DR. Allele-level HLA-DRB1 typing using several DNA-based methods was available for 463 patients. It revealed a known allele mismatch at the DRB1 locus in 30 (6%) of pairs identified as HLA-A and -B match and as HLA-DR potential match. Statistical analysis Estimates of the probability of engraftment, acute GVHD (grades II-IV), chronic GVHD, relapse, and TRM were expressed as cumulative incidence. 27 Survival curves were calculated using the Kaplan-Meier product limit method. 28 The log-rank test 29 was used to test the effect of variables on survival and overall DFS. Variables considered for inclusion in multivariate analysis were those displaying significant association with a transplantation outcome in univariate analysis or for which prior studies suggested a possible prognostic value. Proportional hazards Cox regression model 30 was then used to assess the independent effect of recipient, donor, or transplant characteristics (recipient age, recipient sex, recipient CMV status, donor age, donor sex, donor CMV status, time from diagnosis to transplantation, year of infusion, donor recipient HLA matching, cell dose, use of TBI in the conditioning regimen, T-cell depletion, and MDS subtypes) on transplantation outcomes. Additional variables were included in some analyses eg, history of acute GVHD in the analysis of chronic GVHD and chronic GVHD in the analysis of functional status. Marrow donors and marrow collection Unrelated donors were identified through the NMDP based in Minneapolis, Minnesota. The median time interval between initiation of the preliminary search for a donor and identification of a donor was 5 months (range, months). This interval has decreased over time. Before donation, each volunteer donor underwent complete medical evaluation, received extensive counseling about marrow donation, and signed an intent-to-donate form at the NMDP-approved donor center. Donor characteristics are shown in Table 2. Marrows were collected according to standards established by the NMDP 22 at 95 NMDP-approved collection centers. Harvested marrow was placed in sterile plastic bags and transported to the NMDP-approved transplant centers by courier. Transported marrow was infused without any manipulation in 188 patients and after manipulation to remove ABOincompatible red cells, plasma, or both in 201 patients and to remove T cells in 121 patients. Data collection and outcome definition Data collection methods have been well standardized by the NMDP and have been described in detail. 17,22,23 Donor information, harvest procedure, and recipient information were collected using standardized forms provided by the NMDP. These forms captured baseline information and pretransplantation, transplantation, and posttransplantation events. Follow-up information was reported at 100 days, 6 months, 1 year, and then annually after transplantation. Patient outcome was analyzed to date of last reported follow-up or to date of death. Data reporting for analysis was updated as of September Median follow-up of the surviving patients was 24 months (range, 3-97 months). Engraftment was defined as having occurred on the first of 3 consecutive posttransplantation days on which the absolute neutrophil count (ANC) exceeded 500/ L. Patients who did not achieve this level of ANC at any time after transplantation were considered to have primary graft failure. Patients with initial engraftment in whom severely hypocellular marrow and ANC of less than 500/ L recurred for more than 3 days were considered to have secondary or late graft failure. Patients who survived at least 28 days were considered evaluable for engraftment. Stage of involvement of the skin, liver, and intestinal tract by acute GVHD was determined according to established criteria, 24,25 and an overall grade was assigned on the basis of the sum of individual stages as described. 17 Chronic GVHD was assessed as limited (mild skin involvement only) or extensive (skin, liver, and intestinal tract involvement). 26 Relapse was defined as the recurrence of hematologic abnormalities. Causes of death other than relapse were considered to represent competing risk. Patients who were alive without relapse were censored at last follow-up. TRM was defined as death with no evidence of hematologic relapse. Relapse was considered a competing risk, and patients who were alive without relapse were censored at last follow-up. Disease-free survival (DFS) was defined as survival without morphologic evidence of recurrent MDS. Results Engraftment and graft failure Seventy-three (14%) patients died within the first 27 days of transplantation without evidence of engraftment or GVHD. Of the 437 patients evaluable for engraftment, 380 (87%) achieved sustained donor engraftment and 57 (13%) had graft failure. Twenty-four patients had primary engraftment failure, and 33 had late graft failure. The cumulative incidence of engraftment before day 100 was 84% (95% CI, 82%-86%). Median time to engraftment was 18 days (range, 8-40 days). Recipients of T-cell depleted grafts engrafted faster than recipient of non T-cell depleted grafts 15 days (range, 9-37 days) versus 19 days (range, 8-40 days) (P.02). However, there was no difference in the overall engraftment rate between T-cell and non T-cell depleted grafts at 100 days 83% (range, 78%-88%) versus 85% (range, 83%-87%) (P.66). According to the results of multivariate analysis, higher cell dose, female sex of the patient, male sex of the donor (there was no significant interaction between the sexes of patients and donors), and transplantation between 1994 and 1998 were independently associated with higher rates of engraftment (Table 3). Donor recipient HLA matching and conditioning regimen (TBI containing vs non-tbi containing) did not influence the probability of engraftment in this series of patients. T-cell depletion was removed from the multivariate model for engraftment because T-cell depletion does not obey the proportional hazards model assumption. Cumulative incidence rates were as follows: overall graft failure, 13% (95% CI, 10%-16%); primary graft failure, 5% (95% CI, 3%-7%); late graft failure, 8% (95% CI, 6%-10%). Relapse or residual disease was noted in 8 patients who had primary graft failure and in 10 patients who had late graft failure. In multivariate regression analysis, late graft failure was closely associated with lower cell dose (P.001). MDS subtype, recipient sex, recipient age, CMV status, donor recipient HLA matching, year of infusion, use of TBI-containing preparative regimens, and time to transplantation were not associated with a significant difference in the risk for late graft failure. Nine of the 24 patients with primary graft failure underwent second marrow transplantation, and 2 (8%) were alive at the date of analysis. The other 15 patients died of complications related to pancytopenia before they could undergo second transplantation. Seven of the 33 patients with late graft failure underwent second transplantation, and only one was alive at the time of analysis.

4 1946 CASTRO-MALASPINA et al BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 Table 3. Multivariate proportional hazards regression analysis of transplant outcomes in 510 patients with MDS treated with unrelated donor marrow transplantation RR (95% CI) P Favorable Neutrophil engraftment Cell dose 1.10 ( ).006 Higher Donor sex (female) 0.76 ( ).01 Male Recipient sex (female) 1.24 ( ).05 Female Year of infusion ( ) 0.67 ( ).02 Recent transplantation Acute GVHD Year of infusion ( ) 1.91 ( ).0006 Recent transplantation HLA-A, -B, -DRB1 match 0.65 ( ).02 Match Preparative regimen 1.73 ( ).02 No TBI Relapse RAEB-t 4.92 ( ).0007 RA AML 7.67 ( ).0001 RA Acute GVHD 0.52 ( ).03 Grades II-IV Treatment-related mortality Acute GVHD 2.52 ( ).0001 Grades 0-I HLA-A, -B, -DRB1 match 0.66 ( ).004 Match Recipient CMV serology 1.46 ( ).004 Negative Recipient age 1.13 ( ).005 Younger Donor age 1.20 ( ).01 Younger Overall survival Acute GVHD 2.13 ( ).0001 Grades 0-I AML 2.08 ( ).0001 RA RAEB-t 1.66 ( ).004 RA Cell dose 0.89 ( ).003 Higher Recipient CMV serology 1.44 ( ).002 Negative Time to transplantation ( 9 mo) 0.76 ( ).02 Early transplantation Year of infusion ( ) 1.45 ( ).04 Recent transplantation HLA-A, -B, -DRB1 match 0.78 ( ).05 Match Disease-free survival Acute GVHD 1.93 ( ).0001 Grades 0-I AML 2.04 ( ).0001 RA RAEB-t 1.71 ( ).002 RA Cell dose 0.89 ( ).003 Higher Recipient CMV serology 1.46 ( ).001 Negative Time to transplantation ( 9 mo) 0.78 ( ).03 Early transplantation Year of infusion ( ) 1.43 ( ).03 Recent transplantation including TBI) were independently associated with a lower incidence of grades III and IV acute GVHD (Table 3). The cumulative incidence of limited and extensive chronic GVHD at 2 years after transplantation was 27% (95% CI, 24%-30%). In univariate analysis, patients with a history of grades II to IV acute GVHD, older recipients, patients with refractory anemia (RA), patients receiving T-cell replete marrow grafts and those who received higher cell doses had higher incidences of chronic GVHD. However, in multivariate analysis, only history of grades II to IV acute GVHD was associated with a higher incidence of chronic GVHD after controlling for the transplant center and MDS subtype effects (P.0001). Donor recipient HLA matching was not correlated with chronic GVHD. Relapse Disease recurred after transplantation in 71 (14%) of 506 patients (in 4 patients, the relapse status was unknown). The 2-year cumulative incidence of relapse was 14% (95% CI, 11%-17%). Multivariate analysis demonstrated that relapse was independently associated with MDS subtype (Table 3; Figure 1) and acute GVHD. Patients with RA with excess blasts in transformation (RAEB-t) and patients with MDS in whom AML already developed had higher incidences of relapse than patients with RA. Patients with grades II to IV acute GVHD had lower incidences of relapse. Time to transplantation, donor recipient HLA matching, use of TBI preparative regimen, T-cell depletion, and chronic GVHD were not independently associated with altered risk for relapse after controlling for the transplant center and MDS subtype effects. At the time of analysis, of the 71 MDS patients who had relapse after transplantation, only 4 (6%) were alive with active disease. Six patients died after undergoing second transplantation. Fifteen of the 70 patients with relapsed disease (donor lymphocyte infusion [DLI] data missing for one patient) received infusions of nonirradiated lymphocytes from the original marrow donor. Two patients achieved hematologic remission and subsequently died of other complications. Disease-free survival Of the 506 patients whose survival and relapse status were known, 147 were alive in remission with a median follow-up of 24 months (range, 3-97 months). The estimated probability of disease-free survival (DFS) at 2 years was 29% (95% CI, 25%-33%), and at 4 years it was 26% (95% CI, 22%-30%). DFS according to MDS subtype is shown in Figure 2. Patients with RA and RAEB and Fourteen of the remaining 26 patients recovered marrow function (no chimerism studies are available), and 3 were alive at the date of analysis. Thus, only 4 (12%) of the 33 patients who had late graft failure were long-term survivors. Graft-versus-host disease Of 387 patients with sustained engraftment who survived at least 28 days and who were evaluable for the development of acute GVHD, 211 had grades II to IV acute GVHD. Of these 211 patients, 138 had grade III or IV acute GVHD. The cumulative incidence rate at 100 days of grades II to IV acute GVHD was 47% (95% CI, 43%-51%), and of grades III and IV acute GVHD, it was 32% (95% CI, 28%-36%). In univariate analysis, younger recipient age, T-cell depletion, and lower cell dose were associated with a lower incidence of acute GVHD. Multivariate analysis revealed that donor recipient HLA match, transplantation performed between 1994 and 1998, and use of preparative regimens (not Figure 1. Incidence of relapse according to MDS subtype before transplantation. Relapse status was unavailable for 4 patients.

5 BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 UNRELATED DONOR TRANSPLANTATION FOR MDS 1947 patients with advanced MDS who were in remission or in a second RA phase had better DFS rates than patients with RAEB-t and MDS-related AML. In multivariate analysis, the diagnosis of RA, higher cell dose, recipient CMV seronegativity, transplantation less than 9 months after diagnosis, grade 0 or I acute GVHD (Figure 3), and transplantation from 1994 to 1998 were independently associated with better DFS (Table 3). Recipient age, donor age, donor recipient HLA matching, use of TBI-containing preparative regimens, T-cell depletion, chronic GVHD, and cell dose were not independently associated with any difference in DFS. Analysis of cell dose in recipients of non T-cell depleted marrow grafts revealed that transplantation of a marrow cell dose above the median value of nucleated cells/kg was associated with faster neutrophil engraftment and better DFS (P.0001 and.003, respectively). Analysis of DFS according to etiology, be it idiopathic (n 396), therapy-related (n 70), or postaplastic anemia (n 26), revealed that patients in the latter group did better that those in the 2 other groups (P.02). There was a higher number of patients with RA in the postaplastic anemia group (P.001). DFS rates at 2 years for these groups were 29%, 24%, and 59%, respectively. However, though the DFS remained constant for 4 years after transplantation in the idiopathic and therapy-related groups, it declined and reached a plateau of 34% at approximately 4 years in the postaplastic anemia group. Analysis of DFS according to cytogenetic findings in 361 patients in whom the results of chromosome studies and relapse status were available revealed no significant differences between the 126 patients with normal karyotype and the 235 patients with one or more chromosome abnormalities. DFS rates at 2 years were 34% and 27%, respectively. Analysis of DFS according to the preparative regimen revealed that patients conditioned with busulfan and cyclophosphamide had better overall survival (OS) and DFS rates and lower relapse rates than patients who were not prepared with this regimen (P.03,.01, and.01, respectively; log rank test for OS and DFS and 2 analysis for relapse). In contrast, there were no significant differences in OS, DFS, and relapse rates between patients conditioned with TBI and cyclophosphamide and patients prepared with other preparative regimens. Survival and functional status Of the 510 patients, 152 (30%) were alive 3 months to 8 years after transplantation; 147 were free of disease, 4 had relapsed disease, Figure 3. Probability of DFS according to acute GVHD. and 1 had unknown disease status. The probability of survival at 2 years was 30% (95% CI, 26%-34%), and at 4 years it was 26% (95% CI, 22%-30%). The probability of survival was higher for patients who did not have grades II to IV acute GVHD (P.0009) and for patients with RA (P.008). In multivariate analysis, the diagnosis of RA, higher cell dose, recipient CMV seronegativity, transplantation less than 9 months after diagnosis, transplantation between 1994 and 1998, donor recipient HLA matching, and grade 0 or I acute GVHD were independently associated with better OS (Table 3). The functional status of 86 patients surviving 2 years after transplantation was assessed using the Karnosfky (KPS) or Lansky (LPS) activity scores. Sixty-five (76%) patients had normal or near normal activity scores (KPS/LPS, 90%-100%), and 21 (24%) had significant ongoing limitations (KPS/LPS, 50%-80%). In multivariate analysis, the only parameters associated with inferior KPS/LPS were the use of TBI in the preparative regimen, after controlling for the transplant center and disease status effects, and chronic GVHD. Patients who underwent TBI were less likely to have a KPS/LPS of 90% to 100% than patients who did not undergo TBI (P.03). Causes of death and treatment-related mortality The primary causes of death in 358 (70%) patients are listed in Table 4. Disease relapse was the primary cause of death in 66 (18%) patients. The most common causes of death were treatmentrelated complications, which occurred in 292 (82%) of the 358 patients. Sixty-nine percent of the treatment-related deaths occurred within the first 100 days and 93% within the first year after transplantation. The 2-year cumulative incidence of TRM was 54% (95% CI, 53%-61%). Infections (28%), acute and chronic GVHD (17%), and regimen-related toxicity (17%) were the most frequent complications leading to death. Fungal infections accounted for 42% of the infectious deaths, whereas bacterial infections accounted for 25% and viral infections for approximately 11% of Table 4. Primary causes of death after unrelated donor marrow transplantation in 358 patients with MDS Cause No. patients (%) Figure 2. Probability of DFS according to MDS subtypes. Relapse status was unavailable for 4 patients. Graft failure 8 (2) Regimen-related toxicity 59 (17) Acute and chronic GVHD 60 (17) Infections 101 (28) Other 64 (18) Relapse 66 (18)

6 1948 CASTRO-MALASPINA et al BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 infectious deaths. Pulmonary (21 of 59 patients) and hepatic (16 of 59 patients) toxicities were the most common causes of mortality from regimen-related toxicity. In multivariate analysis, TRM was closely associated with recipient age (Figure 4), donor recipient HLA mismatching (Figure 5), donor age, patient CMV seropositivity, and grades II to IV acute GVHD (Table 3). Discussion Figure 4. Incidence of TRM according to recipient age. Figure 5. Incidence of TRM according to donor recipient HLA matching. This study of a large series of patients with MDS confirms earlier NMDP analysis results in 32 patients that marrow transplants derived from histocompatible, unrelated donors can cure a significant proportion of patients with MDS. 17 The 2-year DFS of 29% was comparable to those reported by the European (28%, n 118 patients) and Japanese (23%, n 33 patients) registries and was slightly lower than the 2-year DFS of 38% reported from the largest American single institution series of 52 patients. 12 The main obstacle to the success of unrelated donor marrow transplantation in this and other series of unrelated donor BMT for MDS 12,14-16 has been the high incidence of fatal transplant-related complications. Comparison of unrelated donor BMT results with those of HLAmatched related BMT clearly shows that the main difference is the higher TRM rate and, consequently, lower DFS rate associated with unrelated donor BMT. When donor recipient relationships were not considered, other patient, disease, transplant, and donor characteristics seemed similar in their influence on the outcomes of either unrelated or related donor BMT. The most significant factors determining a successful outcome in this series of unrelated donor BMT for MDS were disease status before transplantation, level of histocompatibility between donor and recipient, interval from diagnosis to BMT, patient age, patient CMV serologic status, and cell dose. An association of increased risk for graft failure with HLA disparity between donor and recipient was not found in this study. One limitation of the current analysis was that HLA typing was not at the same level of resolution for all patients. However, in the overall series of 5246 patients who received marrow transplants from unrelated donors facilitated by the NMDP, an association between similarly defined HLA disparities and graft failure was demonstrated. 31 HLA disparity has been shown to have a significant correlation with graft failure in related and unrelated donor BMT, though this complication occurs more frequently with unrelated donor transplants. 17,32-35 The basis for the higher incidence of graft failure after unrelated donor transplantation is the greater degree of genetic disparity between unrelated and related donor recipient pairs. This has been demonstrated in several studies in which high-resolution DNA-based techniques have been used for the typing of class 1 and class 2 HLA antigens Why there was an absence of such an association in the subgroup of patients who underwent transplantation for MDS is unclear. The most important variable correlated with the high incidence of acute GVHD in this series was HLA disparity, as shown in other studies. 17,41-44 The higher incidence of acute GVHD in unrelated donor BMT than in related donor BMT for the same level of serologic match is attributed largely to molecular differences in HLA-A, -B, and -DRB1 antigens, which cannot be distinguished by serologic methods but can now be defined by more sensitive high-resolution DNA typing methods Moreover, recent data suggest that mismatches at other class I and class II HLA alleles, particularly HLA-C and HLA-DQB1, which were not taken into consideration for donor selection in this series, also play a role in the development of acute GVHD in recipients of unrelated donor transplants. 34,39,43-46 HLA disparities between donor and recipient also predicted high TRM in this study. This was certainly related to the high incidence of acute and chronic GVHD and associated complications, as shown in this and other series of unrelated donor BMT for MDS 12,14-16 and unrelated donor BMT for aplastic anemia 47 and leukemia. 32,43,48 Other parameters predicting high TRM included increasing recipient age, recipient CMV seropositivity, and donor age. The association of patient age with TRM has been well documented in related donor BMT for MDS 1-9 and in the European 14,15 and the Seattle 12 series of unrelated donor BMT for MDS. Older patients have higher incidences of GVHD and regimenrelated complications. The association of CMV seropositivity of the recipient with a high incidence of CMV disease and TRM after unrelated donor transplantation is also well documented. 49,50 Posttransplantation relapse rates in this series of unrelated donor transplantation were considerably lower than the reported relapse rates after HLA-matched related marrow grafts. 1-9 MDS subtype before transplantation ranked as the single most important prognostic variable affecting relapse risk after either type of transplant. Although patients with more advanced forms of MDS particularly RAEB-t and AML after MDS experienced a similarly high relapse rate after receiving unrelated donor marrow grafts, intermediate forms of MDS, notably RAEB, appeared to

7 BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 UNRELATED DONOR TRANSPLANTATION FOR MDS 1949 have lower relapse rates than those reported in series of related donor BMT. 1-9 This observation suggests that transplants from unrelated donor applied to more indolent forms of MDS have an enhanced graft-versus-leukemia effect. This is consistent with results reported in other series of unrelated donor transplants for MDS, 12 CML, 43 and advanced AML. 48 The reduced incidence of relapse observed among patients with acute GVHD observed in this and the European series 14 may reflect the sensitivity of these forms of MDS to alloreactive T cells, a finding also consistent with the observed sensitivity of relapsed MDS to adoptive transfer of donor lymphocytes from HLA-matched related donors. 51,52 We could not demonstrate a DFS advantage for T-cell depletion in this heterogenous series of patients who underwent transplantation with marrow grafts depleted of T cells by a variety of methods and achieving different degrees of depletion. Similar results were obtained in the analysis of the European series of unrelated donor BMT for MDS. 14 An ongoing prospective trial by the NMDP comparing unmodified to T-cell depleted BMT may clarify the benefits or lack of benefits of T-cell depletion in unrelated donor stem cell transplantation. The current study has identified parameters that influence DFS and that may assist in the timing of transplantation and in determining the quality of the marrow allograft. As in BMT for MDS from HLA-matched siblings 1-9 and unrelated donor BMT for CML, 32,43 patients in this and in the European series 14,15 of unrelated donor BMT for MDS fared better if transplantation was performed soon after diagnosis and at an early stage of disease. Therefore, patients with MDS who are candidates for unrelated donor BMT should initiate an unrelated donor search after the diagnosis is confirmed and should proceed with transplantation without delay once a donor has been identified. This analysis also showed that the use of a BU/CY conditioning regimen was associated with improved DFS and a lower incidence of severe acute GVHD and relapse. Similar encouraging findings with a BU/CY regimen have been reported in a single institution study. 53 Although potential unrecognized selection bias cannot be excluded in a retrospective analysis, these findings suggest that a busulfanbased conditioning regimen may favorably impact the incidence of acute GVHD, TRM, and DFS without compromising the risk for disease recurrence in patients with MDS. Another variable predicting better DFS in this study was higher marrow cell dose. The importance of cell dose in determining successful transplant outcomes has been shown in syngeneic BMT for leukemia, 54 HLA-matched related donor BMT for leukemia, and unrelated donor BMT for CML 32 and advanced AML. 48 The mechanisms involved in this survival benefit are only partly understood. Recent studies 58,59 have shown that one reason is the higher number of hematopoietic stem cells, as measured by CD34 cell content, which correlates with higher engraftment, decreased TRM, and increased DFS rates. Our data confirmed the relationship between cell dose and engraftment, but they did not show a clear correlation of cell dose with TRM. The use of peripheral blood stem cell transplants, which contain higher numbers of stem cells and lymphocytes than marrow transplants, may improve outcomes in patients with MDS. Another finding of our study was that modification of disease status before transplantation resulted in higher DFS because of lower relapse rates. Patients with advanced MDS, particularly RAEB-t and AML after MDS, who had been induced into complete remission or were in a second RA phase before undergoing conditioning, had better DFS and lower relapse rates than patients who underwent transplantation without a change in disease status. The latter group, however, included patients who underwent chemotherapy but did not achieve remission. The beneficial effect of induction of remission before transplantation has been shown in patients with primary or therapy-related MDS who were treated with HLA-matched related BMT. 8,60 However, Anderson et al 61 could not demonstrate an advantage of remission induction in a series of patients with advanced MDS. The issue of pretransplantation chemotherapy is still controversial, and prospective trials are needed to better assess the benefit of this approach. Recent studies 62 report that some patients with advanced MDS can benefit from autologous stem cell transplantation provided they achieve remission with chemotherapy and have an adequate autologous stem cell graft. De Witte et al 15 recently updated the European experience in 126 patients and showed a DFS rate of 33% at 3 years, which is comparable to the DFS rate of 28% observed in this series of patients. Wattel et al 63 report a DFS rate of 42% at 4 years in a prospective trial of autologous stem cell transplantation in MDS. The high incidence of relapse in autologous transplantation is counterbalanced by the high TRM rate in unrelated donor BMT. It is of note, however, that only those patients who achieve sustained remission and who have sufficient numbers of hematopoietic precursor cells can proceed to autologous transplantation. Autologous stem cell transplantation is a valid option for the patient who fulfills these criteria and does not have access to a suitable unrelated donor. Because these conditions occur only in a small fraction of patients with advanced MDS and because unrelated donors are found for more that 50% of patients, unrelated donor stem cell transplantation offers a chance of cure for patients who otherwise have limited long-term survival, even after they achieve remission. 64,65 In summary, the NMDP experience clearly demonstrates that unrelated donor BMT is a valid therapeutic option for patients with MDS and that the best results are achieved in the early stages of disease and within the first year of diagnosis. Although outcome has improved in the past 10 years as a result of improvements in transplantation methodologies and supportive care measures, high TRM rates are still the main factor limiting the success of unrelated donor BMT in MDS. A number of parameters predicting outcomes have been identified in this study, which should facilitate the design of prospective trials exploring new approaches to improve the results of unrelated donor BMT for MDS. The systematic use of high-resolution DNA-based methods for HLA typing and selection of molecularly matched donors, of less toxic preparative regimens, of better GVHD prophylaxis methods, and of higher cell dose peripheral blood stem cell transplantation should result in improved outcome in the next few years. Acknowledgments We thank the members of the MDS Research Study Group Drs Douglas Adkins, Joseph H. Antin, Nancy Bunin, James Casper, William Drobyski, Roger Herzig, Alan F. List, Philip MacCarthy, Margaret O Donnell, George Selby, Mary Territo, Phyllis Warkentin, and John R. Wingard for their valuable and critical comments, and we thank Darlene Kitajima and Maria Matlack of the NMDP staff for their invaluable help at different stages of this study.

8 1950 CASTRO-MALASPINA et al BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 References 1. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82: Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcome analysis according to IPSS score. Leukemia. 1998;12(suppl 1):S25 S Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood. 1993;81: O Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol. 1995;13: Demuynck H, Verhoef GEG, Zachee P, at al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical siblings and alternative donors. Bone Marrow Transplant. 1996;17: Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997;20: Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92: Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Blood. 1996;88: Runde V, De Witte T, Gratwohl A, et al. Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 1998;21: Bunin NJ, Casper JT, Chitambar C, et al. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol. 1988;6: Casper J, Camitta B, Truitt R, et al. Unrelated bone marrow transplants for children with leukemia or myelodysplasia. Blood. 1995;85: Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. Br J Haematol. 1996;93: Davies SM, Wagner JE, Defor T, et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anemia or myelodysplasia. Br J Haematol. 1997;96: Arnold R, De Witte RA, Van Biezen A, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. Bone Marrow Transplant. 1998;21: De Witte T, Herman J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Brt J Haematol. 2000;110: Kodera Y, Morishima Y, Kato S, et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant. 1999;24: Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Bone Marrow Donor Program. N Engl J Med. 1993;328: Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) cooperative group: proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1983; 51: Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for the distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol. 1994;87: Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions and response in acute leukemia. J Clin Oncol. 1990;8: Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: National Marrow Donor Program Standards Committee. Standards of the National Marrow Donor Program. Transfusion. 1993;33: Perkins HA, Hansen JH. The U.S. National Marrow Donor Program. Am J Ped Hematol Oncol. 1994;16: Glucksberg H, Storb R, Fefer A, et al. Clinic manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18: Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15: Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host disease syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69: Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18: Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50: Cox DR. Regression models and life table analysis (with discussions), series B. J Royal Stat Soc B. 1972;34: Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood. 2000;96: McGlave PD, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years of experience of the National Marrow Donor Program. Blood. 2000;95: Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia and lymphoma. N Engl J Med. 1989;320: Bishara A, Amar A, Brautbar C, Condiotti R, Lazarovits V, Nagler A. The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT). Exp Hematol. 1995;23: Petersdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997;89: Santamaria P, Reinsmoen NL, Lindstrom AL, et al. Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA- DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplants pairs. Blood. 1994;83: Nadamanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplants in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood. 1995;86: Petersdorf EW, Longton GM, Anasetti CA, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 1995; 86: Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92: Prasad VK, Kernan NA, Heller G, O Reilly RJ, Yang SY. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood. 1999;93: Davies SM, Shu XO, Blazar BR, et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood. 1995;86: Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donor for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood. 1993;81: Hansen JA, Goley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338: Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998; 339: Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci U S A. 1996;93: Gajewski J, Gjertson D, Cecka M, et al. The impact of T cell depletion on the effects of HLA DRB1 and DQB1 allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3: Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5: Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high risk AML: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89: Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88: Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93: Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:

9 BLOOD, 15 MARCH 2002 VOLUME 99, NUMBER 6 UNRELATED DONOR TRANSPLANTATION FOR MDS Collins RH, Shpilberg O, Drobyski WR, et al. Donor leucocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15: Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngenic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95: Barret AJ, Ringden O, Zhang MJ, et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000;95: Ringden O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose and splenectomy. Transplantation. 1985;40: Paulin T. Importance of bone marrow cell dose in bone marrow transplantation. Clin Transplant. 1992;6: Mavroudis D, Fox M, Read EJ, Carter C, Barrett AJ. Effect of CD34 cell dose on outcome following T cell-depleted marrow transplantation. Blood. 1996;88: Bahceci E, Read EJ, Leitman S, et al. CD34 cell dose predicts relapse and survival after T cell-depleted HLA-identical haematopoietic stem cell transplantation for heamatological malignancies. Br J Haematol. 2000;108: Anasetti C, Heimfeld S, Rowley S, et al. Higher CD34 cell dose is associated with improved survival after marrow transplantation from unrelated donors (abstract). Blood. 1999;94:561a. 60. Yakoub-Agha I, De la Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a long-term study of 70 patients: report of the French Society of Bone Marrow Transplantation. J Clin Oncol. 2000;18: Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997; 89: DeWitte T, Van Biezen AV, Labopin M, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS. Blood. 1997;90: Wattel E, Solary E, Leleu X, et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia. 1999;13: DeWitte T, Suciu S, Peetermans M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia following MDS of more than 6 months duration: a pilot study by the Leukemia Cooperative Group of the EORTC. Leukemia. 1995;11: Beran M, Estey E, O Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999;17:

10 : doi: /blood.v Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program Hugo Castro-Malaspina, Richard E. Harris, James Gajewski, Norma Ramsay, Robert Collins, Bernie Dharan, Roberta King and H. Joachim Deeg Updated information and services can be found at: Articles on similar topics can be found in the following Blood collections Clinical Trials and Observations (4307 articles) Transplantation (2139 articles) Information about reproducing this article in parts or in its entirety may be found online at: Information about ordering reprints may be found online at: Information about subscriptions and ASH membership may be found online at: Blood (print ISSN , online ISSN ), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC Copyright 2011 by The American Society of Hematology; all rights reserved.

KEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus

KEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1

More information

National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants

National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants Biology of Blood and Marrow Transplantation 9:610-615 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0910-0003$30.00/0 doi:10.1016/s1083-8791(03)00329-x National Marrow

More information

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang

More information

The New England Journal of Medicine BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA

The New England Journal of Medicine BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA JOHN A. HANSEN, M.D., THEODORE A. GOOLEY, PH.D., PAUL J. MARTIN, M.D., FREDERICK APPELBAUM, M.D., THOMAS R. CHAUNCEY,

More information

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section: Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:

More information

Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS)

Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) H. Joachim Deeg Myelodysplastic syndrome (MDS) is a hemopoietic stem cell disorder that is potentially curable by transplantation

More information

KEY WORDS: Unrelated SCT, HLA-mismatch, ATG, Graft-versus-host disease

KEY WORDS: Unrelated SCT, HLA-mismatch, ATG, Graft-versus-host disease HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning Regimen Nicolaus Kröger, 1 Tatjana Zabelina,

More information

Reduced-intensity Conditioning Transplantation

Reduced-intensity Conditioning Transplantation Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of

More information

Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( )

Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( ) TRANSPLANTATION Allogeneic hematopoietic stem cell transplantation from family members other than -identical siblings over the last decade (1991-2000) Yoshinobu Kanda, Shigeru Chiba, Hisamaru Hirai, Hisashi

More information

Haplo vs Cord vs URD Debate

Haplo vs Cord vs URD Debate 3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor

More information

HCT for Myelofibrosis

HCT for Myelofibrosis Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis

More information

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014 Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of

More information

Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age

Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age Bone Marrow Transplantation, (1998) 21, 43 49 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age O Ringdén

More information

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital

More information

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,

More information

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient 1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical

More information

Haploidentical Transplantation today: and the alternatives

Haploidentical Transplantation today: and the alternatives Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks

More information

myelodysplastic syndrome MDS MDS MDS

myelodysplastic syndrome MDS MDS MDS myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory

More information

The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children

The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children VOLUME 46 ㆍ NUMBER ㆍ March 0 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children Meerim Park, Kyung

More information

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation for Severe Aplastic Anemia Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center

More information

Hematopoietic Cell Transplantation for Myelofibrosis. Outline

Hematopoietic Cell Transplantation for Myelofibrosis. Outline Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic

More information

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell

More information

Autologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic Leukemia: Comparative Toxicity and Outcomes

Autologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic Leukemia: Comparative Toxicity and Outcomes Biology of Blood and Marrow Transplantation 8:213-220 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Autologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic

More information

Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio

Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0004$32.00/0 doi:10.1016/j.bbmt.2005.06.004 High Disease Burden

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

Introduction to Hematopoietic Stem Cell Transplantation

Introduction to Hematopoietic Stem Cell Transplantation Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British

More information

Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment

Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte

More information

HEMATOLOGIC MALIGNANCIES BIOLOGY

HEMATOLOGIC MALIGNANCIES BIOLOGY HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION

More information

journal of medicine The new england Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia abstract

journal of medicine The new england Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia abstract The new england journal of medicine established in 1812 november 25, 2004 vol. 351 no. 22 Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia Mary

More information

KEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant

KEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,

More information

Clinical Policy: Donor Lymphocyte Infusion

Clinical Policy: Donor Lymphocyte Infusion Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte

More information

Biol Blood Marrow Transplant 17: (2011) Ó 2011 American Society for Blood and Marrow Transplantation

Biol Blood Marrow Transplant 17: (2011) Ó 2011 American Society for Blood and Marrow Transplantation Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related

More information

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms Policy Number: 8.01.21 Last Review: 1/2019 Origination: 12/2001 Next Review: 1/2020 Policy Blue

More information

Hee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim

Hee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia Hee-Je

More information

Donatore HLA identico di anni o MUD giovane?

Donatore HLA identico di anni o MUD giovane? Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events

More information

Marrow Transplants From Unrelated Donors for Patients With Aplastic Anemia: Minimum Effective Dose of Total Body Irradiation

Marrow Transplants From Unrelated Donors for Patients With Aplastic Anemia: Minimum Effective Dose of Total Body Irradiation Biology of Blood and Marrow Transplantation 7:208-215 (2001) 2001 American Society for Blood and Marrow Transplantation ASBMT Marrow Transplants From Unrelated Donors for Patients With Aplastic Anemia:

More information

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant

More information

Recommended Timing for Transplant Consultation

Recommended Timing for Transplant Consultation REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org

More information

Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy?

Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy? Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy? Pierre Fenaux Cohem 2012 Barcelona Should patients with higher risk MDS (or AML

More information

Umbilical Cord Blood Transplantation

Umbilical Cord Blood Transplantation Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results

More information

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single

More information

Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia

Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia 398 Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia Qifa Uu Zhiping Fan Jing Sun Yu Zhang Xiaoli Uu Dan Xu Bing Xu Ru Feng Fanyi Meng Shuyun Zhou Department of Hematology,

More information

AIH, Marseille 30/09/06

AIH, Marseille 30/09/06 ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille

More information

Bone Marrow Transplantation and the Potential Role of Iomab-B

Bone Marrow Transplantation and the Potential Role of Iomab-B Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation

More information

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs

More information

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction

More information

HSCT for Myeloproliferative Disorders. Jane Apperley

HSCT for Myeloproliferative Disorders. Jane Apperley HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an

More information

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia Biology of Blood and Marrow Transplantation 11:713-720 (2005) 2005 American Society for Blood and Marrow Transplantation 1083-8791/05/1109-0008$30.00/0 doi:10.1016/j.bbmt.2005.05.008 Allogeneic Hematopoietic

More information

Cord-Blood Transplantation in Patients with Minimal Residual Disease

Cord-Blood Transplantation in Patients with Minimal Residual Disease The new england journal of medicine Original Article Cord-Blood Transplantation in Patients with Minimal Residual Disease Filippo Milano, M.D., Ph.D., Ted Gooley, Ph.D., Brent Wood, M.D., Ann Woolfrey,

More information

EBMT Complications and Quality of Life Working Party Educational Course

EBMT Complications and Quality of Life Working Party Educational Course EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life

More information

REVIEW ARTICLE. Umbilical Cord Blood Transplantation: Where Do We Stand? ASBMT BB&MT. Raymond C. Wadlow, David L. Porter

REVIEW ARTICLE. Umbilical Cord Blood Transplantation: Where Do We Stand? ASBMT BB&MT. Raymond C. Wadlow, David L. Porter Biology of Blood and Marrow Transplantation 8:637-647 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT REVIEW ARTICLE Umbilical Cord Blood Transplantation: Where Do We Stand? Raymond

More information

Comparable Outcome with T-Cell Depleted Unrelated-Donor versus Related-Donor Allogeneic Bone Marrow Transplantation

Comparable Outcome with T-Cell Depleted Unrelated-Donor versus Related-Donor Allogeneic Bone Marrow Transplantation Biology of Blood and Marrow Transplantation 8:601-607 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Comparable Outcome with T-Cell Depleted Unrelated-Donor versus Related-Donor

More information

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates

More information

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow

More information

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential

More information

Plenary paper. Introduction

Plenary paper. Introduction Plenary paper Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation

More information

Biol Blood Marrow Transplant 18: , 2012 Upfront Allogeneic HSCT following FLAMSA for High-Risk MDS and saml 467

Biol Blood Marrow Transplant 18: , 2012 Upfront Allogeneic HSCT following FLAMSA for High-Risk MDS and saml 467 Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen

More information

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) 3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day

More information

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD. Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific

More information

ASBMT and Marrow Transplantation

ASBMT and Marrow Transplantation Biol Blood Marrow Transplant 19 (2013) 661e675 Brief Articles Improved Survival over the Last Decade in Pediatric Patients Requiring Dialysis after Hematopoietic Cell Transplantation American Society for

More information

Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia Bone Marrow Transplantation, (1998) 22, 1029 1033 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 http://www.stockton-press.co.uk/bmt Intensified conditioning regimen in bone marrow transplantation

More information

Pre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and

Pre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and Pre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and Increased Infection-related Mortality in Patients with Myelodysplastic Syndromes Bart L. Scott 1, 2, J.Y. Park 3, H. Joachim

More information

Transplants for MPD and MDS

Transplants for MPD and MDS Transplants for MPD and MDS The question is really who to transplant, with what and when. Focus on myelofibrosis Jeff Szer Royal Melbourne Hospital Myelodysplasia Little needs to be said Despite new therapies

More information

Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France

Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a

More information

Back to the Future: The Resurgence of Bone Marrow??

Back to the Future: The Resurgence of Bone Marrow?? Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia

More information

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related or matched unrelated donors Immunobiology Working Committee PIs: Peter Shaw and

More information

Clinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias

Clinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias Go Clinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias Number: 0640 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Additional Information

More information

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1. Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic

More information

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1 Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,

More information

CHAPTER 2 PROTOCOL DESIGN

CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN 2.1 ELIGIBILITY CRITERIA Participants fulfilling the following criteria will be eligible for enrollment in the protocol: 1. Participant is diagnosed

More information

Protocol. Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Protocol. Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms Myelodysplastic Syndromes and Myeloproliferative Neoplasms (80121) (Formerly Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms) Medical Benefit Effective

More information

Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes

Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes Advances in Hematology Volume 2011, Article ID 601953, 8 pages doi:10.1155/2011/601953 Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes Jason R. Westin, 1 Rima M. Saliba, 1 Marcos

More information

Clinical Use of Umbilical Cord Blood Hematopoietic Stem Cells

Clinical Use of Umbilical Cord Blood Hematopoietic Stem Cells Biology of Blood and Marrow Transplantation 12:34-41 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0107$32.00/0 doi:10.1016/j.bbmt.2005.09.006 Clinical Use of Umbilical

More information

CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus

CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus Małgorzata Mikulska, 1 Anna Maria Raiola, 2 Paolo Bruzzi, 3 Riccardo

More information

ASBMT. Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation

ASBMT. Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation Biol Blood Marrow Transplant 19 (2013) 247e254 Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation ASBMT American Society for Blood and Marrow

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.

More information

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin s Lymphoma

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin s Lymphoma Biology of Blood and Marrow Transplantation 12:965-972 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1209-0001$32.00/0 doi:10.1016/j.bbmt.2006.05.018 Clinical Outcome following

More information

Transition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology

Transition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent

More information

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care

More information

Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation

Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation Authors: Hirohisa Nakamae, 1 Katharine A. Kirby, 1 Brenda M. Sandmaier, 1,2

More information

BMT CLINICAL TRIALS NETWORK RIC vs. MAC Protocol # 0901 Version 5.0 dated March 3, 2014

BMT CLINICAL TRIALS NETWORK RIC vs. MAC Protocol # 0901 Version 5.0 dated March 3, 2014 Core Study Participants: Baylor College of Medicine (Methodist ) BMT at Northside Hospital Case Western Reserve University Consortia Cleveland Clinic Foundation Oregon Health and Science University University

More information

Donor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma

Donor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma (2002) 29, 65 620 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Donor lymphocyte infusion Prophylactic T cell infusion after T cell-depleted bone marrow transplantation

More information

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:

More information

RIC in Allogeneic Stem Cell Transplantation

RIC in Allogeneic Stem Cell Transplantation RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants

More information

Understanding the role of ex vivo T cell depletion

Understanding the role of ex vivo T cell depletion Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This

More information

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state

More information

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

More information

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

I graft-versus-host disease (GVHD) after allogeneic bone

I graft-versus-host disease (GVHD) after allogeneic bone Acute Upper Gastrointestinal Graft-Versus-Host Disease: Clinical Significance and Response to Immunosuppressive Therapy By Daniel J. Weisdorf, Dale C. Snover, Robert Haake, Wesley J. Miller, Philip B.

More information

Myelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers

Myelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers (23) 32, 35 4 & 23 Nature Publishing Group All rights reserved 268-3369/3 $25. www.nature.com/bmt Myelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers A Daly 1,

More information

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS

More information